Russia faced with shortage of anti-cancer drugs

18 July 2022

The Russian associations of cancer patients have called on the European Coalition of Cancer Patients and the Russian Ministry of Health to conduct additional talks with US pharma major Bristol-Myers Squibb (NYSE: BMY), to continue the supplies of some of the company’s anticancer drugs to the Russian market, reports The Pharma Letter’s local correspondent.

BMS has recently decided to stop trials of its antitumor drug Opdivo (nivolumab) in Russia and withdraw the already launched drug from the market. Thus, hundreds of patients in Russia may remain without the needed medicine.

This has been recently confirmed by representatives of patients’ community in Russia. Olga Badson-Chernyak, head of the public organization "Cancer is curable" in a letter to the Russian Minister of Health Mikhail Murashko, said that, due to the decision of BMS, patients were left without some necessary vital drugs and in some cases remained "without a chance for any therapy to prolong life."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK